ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Go back to ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 48.70 -1.19 (2.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.89 | 52 Week High | $45.58 | |||
| Open | $49.00 | 52 Week Low | $37.82 | |||
| Day High | $49.23 | P/E | N/A | |||
| Day Low | $48.54 | EPS | $0.00 | |||
| Volume | 2,386,015 | |||||
